Macrocyclization of Quinazoline-Based EGFR Inhibitors Leads to Exclusive Mutant Selectivity for EGFR L858R and Del19. J Med Chem. 2022 12 08; 65(23):15679-15697.
View in:
PubMed
Structural Basis for Inhibition of Mutant EGFR with Lazertinib (YH25448). ACS Med Chem Lett. 2022 Dec 08; 13(12):1856-1863.
View in:
PubMed
PH domain-mediated autoinhibition and oncogenic activation of Akt. Elife. 2022 08 15; 11.
View in:
PubMed
Structure of the MRAS-SHOC2-PP1C phosphatase complex. Nature. 2022 09; 609(7926):416-423.
View in:
PubMed
Molecular basis for cooperative binding and synergy of ATP-site and allosteric EGFR inhibitors. Nat Commun. 2022 05 09; 13(1):2530.
View in:
PubMed
A Novel HER2-Selective Kinase Inhibitor Is Effective in HER2 Mutant and Amplified Non-Small Cell Lung Cancer. Cancer Res. 2022 04 15; 82(8):1633-1645.
View in:
PubMed
An allosteric inhibitor against the therapy-resistant mutant forms of EGFR in non-small cell lung cancer. Nat Cancer. 2022 04; 3(4):402-417.
View in:
PubMed
Quinazolinones as allosteric fourth-generation EGFR inhibitors for the treatment of NSCLC. Bioorg Med Chem Lett. 2022 07 15; 68:128718.
View in:
PubMed
Design of a "Two-in-One" Mutant-Selective Epidermal Growth Factor Receptor Inhibitor That Spans the Orthosteric and Allosteric Sites. J Med Chem. 2022 01 27; 65(2):1370-1383.
View in:
PubMed
The structural basis of PTEN regulation by multi-site phosphorylation. Nat Struct Mol Biol. 2021 10; 28(10):858-868.
View in:
PubMed
Allosteric MEK inhibitors act on BRAF/MEK complexes to block MEK activation. Proc Natl Acad Sci U S A. 2021 09 07; 118(36).
View in:
PubMed
Comprehensive functional evaluation of variants of fibroblast growth factor receptor genes in cancer. NPJ Precis Oncol. 2021 Jul 16; 5(1):66.
View in:
PubMed
A structural perspective on targeting the RTK/Ras/MAP kinase pathway in cancer. Protein Sci. 2021 08; 30(8):1535-1553.
View in:
PubMed
The Eya1 Phosphatase Mediates Shh-Driven Symmetric Cell Division of Cerebellar Granule Cell Precursors. Dev Neurosci. 2020; 42(5-6):170-186.
View in:
PubMed
Mutant-Selective Allosteric EGFR Degraders are Effective Against a Broad Range of Drug-Resistant Mutations. Angew Chem Int Ed Engl. 2020 08 17; 59(34):14481-14489.
View in:
PubMed
The protein kinase Akt acts as a coat adaptor in endocytic recycling. Nat Cell Biol. 2020 08; 22(8):927-933.
View in:
PubMed
Structural Basis for EGFR Mutant Inhibition by Trisubstituted Imidazole Inhibitors. J Med Chem. 2020 04 23; 63(8):4293-4305.
View in:
PubMed
Discovery and Optimization of Dibenzodiazepinones as Allosteric Mutant-Selective EGFR Inhibitors. ACS Med Chem Lett. 2019 Nov 14; 10(11):1549-1553.
View in:
PubMed
Architecture of autoinhibited and active BRAF-MEK1-14-3-3 complexes. Nature. 2019 11; 575(7783):545-550.
View in:
PubMed
A driving test for oncogenic mutations. J Biol Chem. 2019 06 14; 294(24):9390-9391.
View in:
PubMed
Single and Dual Targeting of Mutant EGFR with an Allosteric Inhibitor. Cancer Discov. 2019 07; 9(7):926-943.
View in:
PubMed
Discovery and Structural Characterization of ATP-Site Ligands for the Wild-Type and V617F Mutant JAK2 Pseudokinase Domain. ACS Chem Biol. 2019 04 19; 14(4):587-593.
View in:
PubMed
Discovery of a Highly Potent and Broadly Effective Epidermal Growth Factor Receptor and HER2 Exon 20 Insertion Mutant Inhibitor. Angew Chem Int Ed Engl. 2018 09 03; 57(36):11629-11633.
View in:
PubMed
Micro-nano-bio acoustic system for the detection of foodborne pathogens in real samples. Biosens Bioelectron. 2018 Jul 15; 111:52-58.
View in:
PubMed
Correction: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 2018 03 12; 7.
View in:
PubMed
MELK is not necessary for the proliferation of basal-like breast cancer cells. Elife. 2017 09 19; 6.
View in:
PubMed
Crystal Structure of Leiomodin 2 in Complex with Actin: A Structural and Functional Reexamination. Biophys J. 2017 Aug 22; 113(4):889-899.
View in:
PubMed
CRKL Mediates p110ß-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep. 2017 07 18; 20(3):549-557.
View in:
PubMed
Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors. Cancer Res. 2017 05 15; 77(10):2712-2721.
View in:
PubMed
Domain-dependent effects of insulin and IGF-1 receptors on signalling and gene expression. Nat Commun. 2017 03 27; 8:14892.
View in:
PubMed
Leveraging Gas-Phase Fragmentation Pathways for Improved Identification and Selective Detection of Targets Modified by Covalent Probes. Anal Chem. 2016 12 20; 88(24):12248-12254.
View in:
PubMed
Mitotic MELK-eIF4B signaling controls protein synthesis and tumor cell survival. Proc Natl Acad Sci U S A. 2016 08 30; 113(35):9810-5.
View in:
PubMed
Crystal Structure of the FERM-SH2 Module of Human Jak2. PLoS One. 2016; 11(5):e0156218.
View in:
PubMed
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature. 2016 06 02; 534(7605):129-32.
View in:
PubMed
Data publication with the structural biology data grid supports live analysis. Nat Commun. 2016 Mar 07; 7:10882.
View in:
PubMed
SPLINTS: small-molecule protein ligand interface stabilizers. Curr Opin Struct Biol. 2016 Apr; 37:115-22.
View in:
PubMed
EGF-receptor specificity for phosphotyrosine-primed substrates provides signal integration with Src. Nat Struct Mol Biol. 2015 Dec; 22(12):983-90.
View in:
PubMed
Development of Selective Covalent Janus Kinase 3 Inhibitors. J Med Chem. 2015 Aug 27; 58(16):6589-606.
View in:
PubMed
Structure and mechanism of activity-based inhibition of the EGF receptor by Mig6. Nat Struct Mol Biol. 2015 Sep; 22(9):703-711.
View in:
PubMed
Discovery of a BTK/MNK dual inhibitor for lymphoma and leukemia. Leukemia. 2016 Jan; 30(1):173-81.
View in:
PubMed
Activity of the Type II JAK2 Inhibitor CHZ868 in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2015 Jul 13; 28(1):29-41.
View in:
PubMed
Structure of a Bud6/Actin Complex Reveals a Novel WH2-like Actin Monomer Recruitment Motif. Structure. 2015 Aug 04; 23(8):1492-1499.
View in:
PubMed
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res. 2015 Sep 01; 21(17):3913-23.
View in:
PubMed
PARP1-driven poly-ADP-ribosylation regulates BRCA1 function in homologous recombination-mediated DNA repair. Cancer Discov. 2014 Dec; 4(12):1430-47.
View in:
PubMed
Phosphatidylinositol 4,5-bisphosphate triggers activation of focal adhesion kinase by inducing clustering and conformational changes. Proc Natl Acad Sci U S A. 2014 Aug 05; 111(31):E3177-86.
View in:
PubMed
Colon cancer-derived oncogenic EGFR G724S mutant identified by whole genome sequence analysis is dependent on asymmetric dimerization and sensitive to cetuximab. Mol Cancer. 2014 Jun 04; 13:141.
View in:
PubMed
MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells. Elife. 2014 May 20; 3:e01763.
View in:
PubMed
JAK-cytokine receptor recognition, unboxed. Nat Struct Mol Biol. 2014 May; 21(5):431-3.
View in:
PubMed
Inhibition of KRAS-driven tumorigenicity by interruption of an autocrine cytokine circuit. Cancer Discov. 2014 Apr; 4(4):452-65.
View in:
PubMed
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med. 2013 Dec 18; 5(216):216ra177.
View in:
PubMed
Cetuximab response of lung cancer-derived EGF receptor mutants is associated with asymmetric dimerization. Cancer Res. 2013 Nov 15; 73(22):6770-9.
View in:
PubMed
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci U S A. 2013 Sep 17; 110(38):E3595-604.
View in:
PubMed
Structure of a pseudokinase-domain switch that controls oncogenic activation of Jak kinases. Nat Struct Mol Biol. 2013 Oct; 20(10):1221-3.
View in:
PubMed
Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. ACS Chem Biol. 2013 Sep 20; 8(9):1931-8.
View in:
PubMed
Structure and ubiquitination-dependent activation of TANK-binding kinase 1. Cell Rep. 2013 Mar 28; 3(3):747-58.
View in:
PubMed
Structure of the formin-interaction domain of the actin nucleation-promoting factor Bud6. Proc Natl Acad Sci U S A. 2012 Dec 11; 109(50):E3424-33.
View in:
PubMed
Functional analysis of receptor tyrosine kinase mutations in lung cancer identifies oncogenic extracellular domain mutations of ERBB2. Proc Natl Acad Sci U S A. 2012 Sep 04; 109(36):14476-81.
View in:
PubMed
Cyclic di-GMP sensing via the innate immune signaling protein STING. Mol Cell. 2012 Jun 29; 46(6):735-45.
View in:
PubMed
EGFR in limbo. Cell. 2012 May 11; 149(4):735-7.
View in:
PubMed
Functional characterization of an isoform-selective inhibitor of PI3K-p110ß as a potential anticancer agent. Cancer Discov. 2012 May; 2(5):425-33.
View in:
PubMed
Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition. J Exp Med. 2012 Feb 13; 209(2):259-73.
View in:
PubMed
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res. 2012 Mar 15; 18(6):1790-7.
View in:
PubMed
Tyrosine phosphorylation of Rac1: a role in regulation of cell spreading. PLoS One. 2011; 6(12):e28587.
View in:
PubMed
Structure and function of the interacting domains of Spire and Fmn-family formins. Proc Natl Acad Sci U S A. 2011 Jul 19; 108(29):11884-9.
View in:
PubMed
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov. 2011 Jun; 1(1):78-89.
View in:
PubMed
Crystal structure of a coiled-coil domain from human ROCK I. PLoS One. 2011 Mar 21; 6(3):e18080.
View in:
PubMed
Binucleine 2, an isoform-specific inhibitor of Drosophila Aurora B kinase, provides insights into the mechanism of cytokinesis. ACS Chem Biol. 2010 Nov 19; 5(11):1015-20.
View in:
PubMed
The FERM domain: organizing the structure and function of FAK. Nat Rev Mol Cell Biol. 2010 Nov; 11(11):802-14.
View in:
PubMed
The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res. 2010 Dec 15; 70(24):10038-43.
View in:
PubMed
Crystal structure of a complex between amino and carboxy terminal fragments of mDia1: insights into autoinhibition of diaphanous-related formins. PLoS One. 2010 Sep 30; 5(9).
View in:
PubMed
Structural basis for the recognition of N-end rule substrates by the UBR box of ubiquitin ligases. Nat Struct Mol Biol. 2010 Oct; 17(10):1175-81.
View in:
PubMed
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature. 2009 Dec 24; 462(7276):1070-4.
View in:
PubMed
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta. 2010 Mar; 1804(3):559-66.
View in:
PubMed
[Palmar wrist arthroscopy for evaluation of concomitant carpal lesions in operative treatment of distal intraarticular radius fractures]. Handchir Mikrochir Plast Chir. 2009 Oct; 41(5):295-9.
View in:
PubMed
The interplay of structural information and functional studies in kinase drug design: insights from BCR-Abl. Curr Opin Cell Biol. 2009 Apr; 21(2):288-95.
View in:
PubMed
Crystal structures of the FAK kinase in complex with TAE226 and related bis-anilino pyrimidine inhibitors reveal a helical DFG conformation. PLoS One. 2008; 3(11):e3800.
View in:
PubMed
The Skap-hom dimerization and PH domains comprise a 3'-phosphoinositide-gated molecular switch. Mol Cell. 2008 Nov 21; 32(4):564-75.
View in:
PubMed
The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008 Feb 12; 105(6):2070-5.
View in:
PubMed
Spatial and temporal regulation of focal adhesion kinase activity in living cells. Mol Cell Biol. 2008 Jan; 28(1):201-14.
View in:
PubMed
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell. 2007 Jul; 12(1):81-93.
View in:
PubMed
Structural basis for the autoinhibition of focal adhesion kinase. Cell. 2007 Jun 15; 129(6):1177-87.
View in:
PubMed
Structure of the FH2 domain of Daam1: implications for formin regulation of actin assembly. J Mol Biol. 2007 Jun 22; 369(5):1258-69.
View in:
PubMed
Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr; 3(4):229-38.
View in:
PubMed
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell. 2007 Mar; 11(3):217-27.
View in:
PubMed
Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem. 2007; 76:593-627.
View in:
PubMed
Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors. Proc Natl Acad Sci U S A. 2006 May 16; 103(20):7817-22.
View in:
PubMed
Structure of the autoinhibitory switch in formin mDia1. Structure. 2006 Feb; 14(2):257-63.
View in:
PubMed
Crystal structure of the FERM domain of focal adhesion kinase. J Biol Chem. 2006 Jan 06; 281(1):252-9.
View in:
PubMed
Crystal structure of the Jak3 kinase domain in complex with a staurosporine analog. Blood. 2005 Aug 01; 106(3):996-1002.
View in:
PubMed
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005 Apr; 7(4):387-97.
View in:
PubMed
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005 Feb 24; 352(8):786-92.
View in:
PubMed
A case of metastasizing invasive hydatidiform mole. Is less--less good? Review of the literature with regard to adequate treatment. Eur J Gynaecol Oncol. 2005; 26(2):158-62.
View in:
PubMed
Structure and regulation of Src family kinases. Oncogene. 2004 Oct 18; 23(48):7918-27.
View in:
PubMed
Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell. 2004 Jul; 6(1):33-43.
View in:
PubMed
Identifying and characterizing a novel activating mutation of the FLT3 tyrosine kinase in AML. Blood. 2004 Sep 15; 104(6):1855-8.
View in:
PubMed
FERM domain interaction promotes FAK signaling. Mol Cell Biol. 2004 Jun; 24(12):5353-68.
View in:
PubMed
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004 Jun 04; 304(5676):1497-500.
View in:
PubMed
SAP increases FynT kinase activity and is required for phosphorylation of SLAM and Ly9. Int Immunol. 2004 May; 16(5):727-36.
View in:
PubMed
Crystal structures of a Formin Homology-2 domain reveal a tethered dimer architecture. Cell. 2004 Mar 05; 116(5):711-23.
View in:
PubMed
A conserved mechanism for Bni1- and mDia1-induced actin assembly and dual regulation of Bni1 by Bud6 and profilin. Mol Biol Cell. 2004 Feb; 15(2):896-907.
View in:
PubMed
Proteomics-based target identification: bengamides as a new class of methionine aminopeptidase inhibitors. J Biol Chem. 2003 Dec 26; 278(52):52964-71.
View in:
PubMed
The SAP and SLAM families in immune responses and X-linked lymphoproliferative disease. Nat Rev Immunol. 2003 Oct; 3(10):813-21.
View in:
PubMed
A zinc clasp structure tethers Lck to T cell coreceptors CD4 and CD8. Science. 2003 Sep 19; 301(5640):1725-8.
View in:
PubMed
Structural basis of degradation signal recognition by SspB, a specificity-enhancing factor for the ClpXP proteolytic machine. Mol Cell. 2003 Jul; 12(1):75-86.
View in:
PubMed
Structural basis for negative regulation of hypoxia-inducible factor-1alpha by CITED2. Nat Struct Biol. 2003 Jul; 10(7):504-12.
View in:
PubMed
Assembling atomic resolution views of the immunological synapse. Curr Opin Immunol. 2003 Jun; 15(3):286-93.
View in:
PubMed
Origins of peptide selectivity and phosphoinositide binding revealed by structures of disabled-1 PTB domain complexes. Structure. 2003 May; 11(5):569-79.
View in:
PubMed
SAP couples Fyn to SLAM immune receptors. Nat Cell Biol. 2003 Feb; 5(2):155-60.
View in:
PubMed
Homotetrameric structure of the SNAP-23 N-terminal coiled-coil domain. J Biol Chem. 2003 Apr 11; 278(15):13462-7.
View in:
PubMed
Specificity in signaling by c-Yes. Front Biosci. 2003 Jan 01; 8:s185-205.
View in:
PubMed
Structural basis for recruitment of CBP/p300 by hypoxia-inducible factor-1 alpha. Proc Natl Acad Sci U S A. 2002 Apr 16; 99(8):5367-72.
View in:
PubMed
Mutant tyrosine kinases with unnatural nucleotide specificity retain the structure and phospho-acceptor specificity of the wild-type enzyme. Chem Biol. 2002 Jan; 9(1):25-33.
View in:
PubMed
Structure of a human Tcf4-beta-catenin complex. Nat Struct Biol. 2001 Dec; 8(12):1053-7.
View in:
PubMed
Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells. EMBO J. 2001 Nov 01; 20(21):5840-52.
View in:
PubMed
Mapping of epitopes in discoidin domain receptor 1 critical for collagen binding. J Biol Chem. 2001 Dec 07; 276(49):45952-8.
View in:
PubMed
Characterization of SH2D1A missense mutations identified in X-linked lymphoproliferative disease patients. J Biol Chem. 2001 Sep 28; 276(39):36809-16.
View in:
PubMed
Implications for familial hypercholesterolemia from the structure of the LDL receptor YWTD-EGF domain pair. Nat Struct Biol. 2001 Jun; 8(6):499-504.
View in:
PubMed
Structure of the cooperative allosteric anthranilate synthase from Salmonella typhimurium. Nat Struct Biol. 2001 Mar; 8(3):243-7.
View in:
PubMed
Structure of PAK1 in an autoinhibited conformation reveals a multistage activation switch. Cell. 2000 Aug 04; 102(3):387-97.
View in:
PubMed
Structure of a WW domain containing fragment of dystrophin in complex with beta-dystroglycan. Nat Struct Biol. 2000 Aug; 7(8):634-8.
View in:
PubMed
Adapting to multiple personalities: Cbl is also a RING finger ubiquitin ligase. Biochim Biophys Acta. 2000 Jul 31; 1471(1):M1-M12.
View in:
PubMed
Crystal structures of the XLP protein SAP reveal a class of SH2 domains with extended, phosphotyrosine-independent sequence recognition. Mol Cell. 1999 Oct; 4(4):555-61.
View in:
PubMed
The Cbl protooncoprotein: a negative regulator of immune receptor signal transduction. Immunol Today. 1999 Aug; 20(8):375-82.
View in:
PubMed
Crystal structure of the pleckstrin homology-phosphotyrosine binding (PH-PTB) targeting region of insulin receptor substrate 1. Proc Natl Acad Sci U S A. 1999 Jul 20; 96(15):8378-83.
View in:
PubMed
Crystal structures of c-Src reveal features of its autoinhibitory mechanism. Mol Cell. 1999 May; 3(5):629-38.
View in:
PubMed
Structure of the amino-terminal domain of Cbl complexed to its binding site on ZAP-70 kinase. Nature. 1999 Mar 04; 398(6722):84-90.
View in:
PubMed
Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression. Biochem J. 1998 Nov 01; 335 ( Pt 3):557-65.
View in:
PubMed
A Zn2+ ion links the cytoplasmic tail of CD4 and the N-terminal region of Lck. J Biol Chem. 1998 Jul 24; 273(30):18729-33.
View in:
PubMed
Crystal structure of the tyrosine phosphatase SHP-2. Cell. 1998 Feb 20; 92(4):441-50.
View in:
PubMed
Peptide and protein phosphorylation by protein tyrosine kinase Csk: insights into specificity and mechanism. Biochemistry. 1998 Jan 06; 37(1):165-72.
View in:
PubMed
Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E- deficient mouse hepatocytes. J Clin Invest. 1997 Dec 01; 100(11):2915-22.
View in:
PubMed
Three-dimensional structure of the tyrosine kinase c-Src. Nature. 1997 Feb 13; 385(6617):595-602.
View in:
PubMed
Analysis of the physical properties and molecular modeling of Sec13: A WD repeat protein involved in vesicular traffic. Biochemistry. 1996 Dec 03; 35(48):15215-21.
View in:
PubMed
Phosphorylated T cell receptor zeta-chain and ZAP70 tandem SH2 domains form a 1:3 complex in vitro. Eur J Biochem. 1996 Jun 01; 238(2):440-5.
View in:
PubMed
Structure of the IRS-1 PTB domain bound to the juxtamembrane region of the insulin receptor. Cell. 1996 May 31; 85(5):695-705.
View in:
PubMed
Crystal structure of the PI 3-kinase p85 amino-terminal SH2 domain and its phosphopeptide complexes. Nat Struct Biol. 1996 Apr; 3(4):364-74.
View in:
PubMed
Spatial constraints on the recognition of phosphoproteins by the tandem SH2 domains of the phosphatase SH-PTP2. Nature. 1996 Jan 18; 379(6562):277-80.
View in:
PubMed
A new flavor in phosphotyrosine recognition. Structure. 1995 May 15; 3(5):421-4.
View in:
PubMed
SH3 domains. Minding your p's and q's. Curr Biol. 1995 Apr 01; 5(4):364-7.
View in:
PubMed
Catalytic specificity of protein-tyrosine kinases is critical for selective signalling. Nature. 1995 Feb 09; 373(6514):536-9.
View in:
PubMed
Two crystal forms of the extracellular domain of type I tumor necrosis factor receptor. J Mol Biol. 1994 Jun 03; 239(2):332-5.
View in:
PubMed
Role of acidic amino acids in the allosteric modulation by gallamine of antagonist binding at the m2 muscarinic acetylcholine receptor. Mol Pharmacol. 1994 May; 45(5):983-90.
View in:
PubMed
Structure of the regulatory domains of the Src-family tyrosine kinase Lck. Nature. 1994 Apr 21; 368(6473):764-9.
View in:
PubMed
Recognition of a high-affinity phosphotyrosyl peptide by the Src homology-2 domain of p56lck. Nature. 1993 Mar 04; 362(6415):87-91.
View in:
PubMed
The structure of human lymphotoxin (tumor necrosis factor-beta) at 1.9-A resolution. J Biol Chem. 1992 Feb 05; 267(4):2119-22.
View in:
PubMed
The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989 Oct 15; 264(29):17595-605.
View in:
PubMed